# ROsuvastatin Pretreatment to Reduce MyocArdial Periprocedural Necrosis:Comparison With Atorvastatin Reloading

> **NCT01228227** · PHASE3 · COMPLETED · sponsor: **Gennaro Sardella** · enrollment: 310 (estimated)

## Conditions studied

- Assess the Periprocedural Myocardial Necrosis

## Interventions

- **DRUG:** ATORVASTATIN 80 mg
- **DRUG:** ROSUVASTATIN 40 mg

## Key facts

- **NCT ID:** NCT01228227
- **Lead sponsor:** Gennaro Sardella
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2011-04
- **Final completion:** 2011-08
- **Target enrollment:** 310 (ESTIMATED)
- **Last updated:** 2013-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01228227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01228227, "ROsuvastatin Pretreatment to Reduce MyocArdial Periprocedural Necrosis:Comparison With Atorvastatin Reloading". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01228227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*